680 articles in this topic
Phase I trial of Temab-A reports 15.6% response rate and 74.6% disease control in heavily pretreated metastatic colorectal cancer patients.
A new DNA-based treatment blocks the PCSK9 protein, cutting LDL cholesterol by nearly 50% while avoiding common statin side effects.
A large WHO pharmacovigilance analysis reveals which myeloma drugs most strongly signal autonomic, motor, and sensory nerve damage.
Activated T cells release vesicles carrying genomic DNA that reprogram recipient cells to display tumor antigens more effectively.
Fibrotic tissue stiffness activates a cascade that recruits immune cells and generates DNA-damaging aldehydes, linking dense breast tissue to cancer risk.
Phase 1 trial shows MP0317 activates anti-tumor immunity in solid tumors with a favorable safety profile, supporting combination therapy.
RO7300490, a FAP-targeted CD40 agonist, proved manageable in 80 advanced cancer patients but produced no objective tumor responses despite clear immune activation.
A first-in-human trial shows CAR-modified stem cell memory T cells outperform standard CAR T cells in expansion, persistence, and complete responses.
New research shows that the level of RAS oncogene activity determines whether cells become senescent or tumorigenic — a key cancer-prevention insight.
Dive deep into the molecular machinery of genomic instability — from telomere-driven crisis states and epigenetic remodeling at break sites to cutting-edge therapeutic strategies targeting DNA repair fidelity in aging and cancer.
Discover what DNA actually is, how everyday threats like sunlight and stress can damage it, and why protecting your genetic code is the secret to a longer, healthier life.
Zongertinib (Hernexeos) wins FDA approval for unresectable or metastatic HER2-mutant non-squamous NSCLC, expanding targeted therapy options.
